Back to top
more

Nektar Therapeutics (NKTR)

(Delayed Data from NSDQ)

$22.56 USD

22.56
304,852

-0.71 (-3.05%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $22.59 +0.03 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

by Zacks Equity Research

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

Zacks Equity Research

Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?

by Zacks Equity Research

Nektar (NKTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 5.56% and -18.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

by Zacks Equity Research

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

Zacks Equity Research

Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).

Zacks Equity Research

Is a Surprise Coming for Nektar (NKTR) This Earnings Season?

by Zacks Equity Research

Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study

by Zacks Equity Research

Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.

Zacks Equity Research

Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

Zacks Equity Research

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

by Zacks Equity Research

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

Zacks Equity Research

Why Is Nektar (NKTR) Up 3% Since Last Earnings Report?

by Zacks Equity Research

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat

by Zacks Equity Research

Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.

Zacks Equity Research

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 23.75% and 39.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

by Zacks Equity Research

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

Zacks Equity Research

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?

by Zacks Equity Research

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.